Progress and introduction
of main products
Non-Invasive Oral Delivery: Provides a convenient, patient-friendly alternative to injections
Innovative Formulation: Engineered to resist GI degradation, ensuring effective absorption
Superior Bioactivity: Enhances TL1A inhibition for stronger anti-inflammatory effects
Unique Epitope Targeting: Ensures high specificity and optimized immune modulation
Minimal Immunocomplex Formation: Reduces immunogenicity and enhances safety
Optimized Pharmacokinetics: Improves stability, bioavailability, and local absorption
The oral TL-1A antibody works by:
Inhibiting TL-1A/DR3 Signaling: Reducing the release of key pro-inflammatory cytokines such as IFNγ
Exerting Local Effects: High bioavailability ensures targeted modulation of GI immune responses, reducing inflammation and supporting repair Indications
IBD – Crohn’s Disease, Ulcerative Colitis
Route: Oral (capsule)
Distribution: Sufficient stability in the GI tract and enhanced local absorption, supporting effective dosing regimens
